DEF: Tenaya Therapeutics 2026 Proxy Statement Overview

Tenaya Therapeutics has filed its 2026 proxy statement, seeking stockholder approval for director elections, auditor ratification, and an amendment to its 2021 Equity Incentive Plan.

Summary

• The company will hold its 2026 Annual Meeting of Stockholders virtually on May 27, 2026.
• Stockholders are asked to elect three Class II directors: Amy Burroughs, Karah Parschauer, and Catherine Stehman-Breen.
• The company seeks to ratify the appointment of Deloitte & Touche LLP as its independent registered public accounting firm for fiscal year 2026.
• Stockholders are asked to approve an amendment and restatement of the 2021 Equity Incentive Plan, which includes a one-time increase of approximately 3% of outstanding shares (6,509,966 shares) and the removal of the 4 million share annual cap from the evergreen provision.
• As of the April 1, 2026 record date, there were 216,998,876 shares of common stock outstanding.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing focused on governance and compensation structure, reflecting the company's efforts to stabilize its internal incentive programs amidst a difficult market environment.

Positives

• The company has maintained a disciplined approach to equity usage, with annual dilution rates reported as low relative to peer companies.
• The proposed equity plan amendment is intended to bring equity reserves back in line with peer benchmarks to support talent retention.
• The company has implemented a clawback policy in compliance with SEC and Nasdaq rules.
• The board maintains a separation of the Chair and CEO roles, which is intended to reinforce independent oversight.

Negatives

• The company has experienced a significant reduction in workforce, with over 50% of staff cut since 2024.
• The company's current equity overhang is well below the 25th percentile of its peer group, which the board indicates has constrained its ability to grant market-competitive awards.
• The company's stock price has faced downward pressure, with a closing price of $0.6810 as of April 1, 2026.

Risks

• Failure to approve the amended equity plan could disadvantage the company in attracting and retaining specialized talent in the competitive San Francisco Bay area.
• Reliance on cash-based compensation alternatives in lieu of equity could reduce cash available for product pipeline development.
• The company faces inherent risks related to its clinical-stage biopharmaceutical business model, including regulatory and development milestones.

Future Outlook

The company intends to continue its focus on research and development, utilizing equity incentives to attract and retain talent necessary to achieve strategic priorities and business milestones.

Management Comments

• The board believes that a market-competitive equity program is a necessary and powerful employee incentive and retention tool that benefits stockholders.
• The company remains committed to managing its cash reserves carefully while using equity incentives to reinforce stockholder alignment.

Industry Context

StockSavvy.ai notes that Tenaya Therapeutics is navigating a challenging environment for clinical-stage biotechs, characterized by the need to balance cash preservation with the necessity of competitive equity-based compensation to retain specialized talent in a high-cost labor market.

Comparison to Industry Standards

• The company's current issued overhang of 8.2% is significantly below the peer group median of 16.4%.
• The company's total overhang of 10.2% is below the peer group 25th percentile of 19.0%.
• The company's 3-year average burn rate of 4.4% is below the peer group median.
• The proposed 4% evergreen provision is lower than the 5% provision maintained by 70% of peers with such provisions.

Corporate Governance

Related Party Transactions

• The company engaged in various stock, pre-funded warrant, and warrant issuances in 2024 and 2025 involving entities affiliated with The Column Group, which is a major stockholder and represented on the board.

Stakeholder Impact

• Stockholders are asked to vote on proposals that will impact share dilution.
• Employees and consultants are the primary beneficiaries of the proposed equity plan changes.
• The company continues to prioritize retention of core talent following significant workforce reductions.

Next Steps

• Hold the Annual Meeting of Stockholders on May 27, 2026.
• Tabulate votes for director elections, auditor ratification, and the equity plan amendment.
• File a Form 8-K with the SEC within four business days after the meeting to disclose voting results.

Key Dates

Keywords

Tenaya Therapeutics, TNYA, Proxy Statement, Equity Incentive Plan, Biotechnology, Corporate Governance, Annual Meeting